Why Do Innovative Drugs Always Die and Need to Be Resurrected?

The Harvard Biotech Club is hosting a talk and Q&A session with Dr. Ann
Kwong, Founder and CEO of Trek Therapeutics and InnovaTID Pharmaceuticals.
She will share her first-hand experiences with the discovery of
telaprevir (VX-950,
INCIVEKTM), a protease inhibitor for Genotype 1 HCV infection.

Ann Kwong is an industry leader in antiviral drug discovery with more than
20 years’ experience developing successful drug candidates. She founded the
Infectious Diseases group at Vertex which played a leading role in the
research, development, and commercialization of telaprevir (INCIVEK™), a
HCV protease inhibitor and VX-787, a PB2 influenza virus inhibitor. She is
a founding member of HCV DRAG (HCV Drug Development Advisory Group), a
consortium of industry leaders, clinical trial leaders, and community

WHEN: *Thursday, January 7th, 5:00 - 6:00 PM*

WHERE: *TMEC Rm 227*, Harvard Medical School, 260 Longwood Ave., Boston MA

Pizza and refreshments will be provided.

Please RSVP here: